CA2341522A1 - Nouvelle forme saline pharmaceutique - Google Patents
Nouvelle forme saline pharmaceutique Download PDFInfo
- Publication number
- CA2341522A1 CA2341522A1 CA002341522A CA2341522A CA2341522A1 CA 2341522 A1 CA2341522 A1 CA 2341522A1 CA 002341522 A CA002341522 A CA 002341522A CA 2341522 A CA2341522 A CA 2341522A CA 2341522 A1 CA2341522 A1 CA 2341522A1
- Authority
- CA
- Canada
- Prior art keywords
- salt
- agent
- base
- useful
- saccharinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un sel de saccharinate de bases organiques médicinales qui ne sont pas des alcaloïdes, et constituant une nouvelle forme saline présentant des propriétés organoleptiques améliorées et une solubilité réduite.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9815498P | 1998-08-27 | 1998-08-27 | |
US60/098,154 | 1998-08-27 | ||
PCT/US1999/019575 WO2000012067A1 (fr) | 1998-08-27 | 1999-08-26 | Nouvelle forme saline pharmaceutique |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2341522A1 true CA2341522A1 (fr) | 2000-03-09 |
Family
ID=22267557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002341522A Abandoned CA2341522A1 (fr) | 1998-08-27 | 1999-08-26 | Nouvelle forme saline pharmaceutique |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1107738A4 (fr) |
JP (1) | JP2003525855A (fr) |
CN (1) | CN1348363A (fr) |
AU (1) | AU6021199A (fr) |
CA (1) | CA2341522A1 (fr) |
WO (1) | WO2000012067A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177294A1 (fr) | 2022-03-18 | 2023-09-21 | Plethora Therapeutics B.V. | Administration transmucosale de composés psychoactifs |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19940740A1 (de) * | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
DE10013712A1 (de) * | 2000-03-20 | 2001-09-27 | Nutrinova Gmbh | Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung |
DE10045521A1 (de) | 2000-03-31 | 2001-10-04 | Roche Diagnostics Gmbh | Nukleinsäureamplifikationen |
US20050176790A1 (en) * | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
DE10130504B4 (de) | 2001-06-25 | 2005-02-03 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Xanthin- und Phenazon-Acesulfam-H-Komplexe mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung |
WO2007025177A2 (fr) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenese par modulation du recepteur muscarinique |
EP2258358A3 (fr) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenèse avec un inhibiteur de l'acetylcholinestérase |
EP2377530A3 (fr) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation de neurogénèse par inhibition PDE |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (fr) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogénèse par modulation de l'angiotensine |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CN101918418A (zh) * | 2007-12-12 | 2010-12-15 | 阿尔迪默菲克斯技术有限责任公司 | 替诺福韦地索普西的固体形式 |
US7935817B2 (en) | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
WO2010099217A1 (fr) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine |
DE202010001237U1 (de) | 2010-01-21 | 2010-04-01 | Grünenthal GmbH | Kombination aus Tramadol und Acetaminophen als Brausetablette |
EP2592078A1 (fr) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3 |
TW201517906A (zh) * | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
CN107868117B (zh) * | 2016-09-28 | 2021-04-23 | 中国科学院苏州纳米技术与纳米仿生研究所 | 司坦唑醇糖精盐及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1288002A (fr) * | 1954-06-14 | 1962-03-24 | Pfizer & Co C | Perfectionnements apportés aux procédés de fabrication de composés d'imidazoline |
ES271829A1 (es) * | 1960-12-19 | 1962-03-01 | Tanabe Seiyaku Co | Un procedimiento para preparar una sal comestible de acido benzofenoma-2-carboxilico y 1-metil-3-(di-2-tienilmetilen) piperidina |
US4711784A (en) * | 1986-01-07 | 1987-12-08 | Warner-Lambert Company | Encapsulation composition for use with chewing gum and edible products |
US5837277A (en) * | 1992-06-04 | 1998-11-17 | Smithkline Beecham Corporation | Palatable pharmaceutical compositions |
-
1999
- 1999-08-26 CN CN99810139A patent/CN1348363A/zh active Pending
- 1999-08-26 AU AU60211/99A patent/AU6021199A/en not_active Abandoned
- 1999-08-26 WO PCT/US1999/019575 patent/WO2000012067A1/fr not_active Application Discontinuation
- 1999-08-26 EP EP99968215A patent/EP1107738A4/fr not_active Withdrawn
- 1999-08-26 JP JP2000567187A patent/JP2003525855A/ja active Pending
- 1999-08-26 CA CA002341522A patent/CA2341522A1/fr not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177294A1 (fr) | 2022-03-18 | 2023-09-21 | Plethora Therapeutics B.V. | Administration transmucosale de composés psychoactifs |
NL2031332B1 (en) * | 2022-03-18 | 2023-09-29 | Plethora Therapeutics B V | Transmucosal delivery of psychoactive compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1107738A4 (fr) | 2003-01-22 |
WO2000012067A1 (fr) | 2000-03-09 |
EP1107738A1 (fr) | 2001-06-20 |
AU6021199A (en) | 2000-03-21 |
JP2003525855A (ja) | 2003-09-02 |
CN1348363A (zh) | 2002-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2341522A1 (fr) | Nouvelle forme saline pharmaceutique | |
US5811436A (en) | Oral liquid compositions containing paroxetine resinate | |
US6306904B1 (en) | Antihistaminic/antitussive compositions | |
US20030083354A1 (en) | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions | |
EP1082109B1 (fr) | Composition orale comprenant un biguanide et un acide organique | |
US6037358A (en) | Decongestant/antihistaminic compositions | |
EP1778183B1 (fr) | Compositions liquides de paroxetine | |
HU204994B (en) | Process for producint new ranitidine derivatives and pharmaceutical compositions comprising same | |
KR850001883B1 (ko) | 결정성 벤조티아진 디옥시드 염류의 제조방법 | |
RU2004123612A (ru) | Фармацевтическая композиция для перорального применения | |
JP3465820B2 (ja) | トロバフロキサシン経口懸濁剤 | |
US6462094B1 (en) | Decongestant/expectorant compositions | |
EP1747781B1 (fr) | Preparation pharmaceutique orale de fosfomycine stable et destinee a des diabetiques | |
EP0194336A2 (fr) | Formulation orale de mobenzoxamine | |
SK15472001A3 (sk) | Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu liečiva použiteľného na liečenie alebo prevenciu porúch nálady, porúch adaptácie alebo stavov úzkosti a depresie | |
CA2008183C (fr) | Composition pharmaceutique liquide pour derives du piperidinealcanol | |
EP1452169A1 (fr) | Compositions pharmaceutiques liquides de base aqueuse en forme de suspension destinnees a l'administration par voie orale d'ibuprofene | |
MXPA01000867A (en) | Novel pharmaceutical salt form | |
US6586469B2 (en) | Antihistaminic/antitussive compositions | |
WO2003086356A1 (fr) | Compositions de formes dosifiees solides de tannate de diphenhydramine et procedes d'utilisation associes | |
US6566396B2 (en) | Antitussive/antihistaminic compositions | |
JPS6350355B2 (fr) | ||
US20030044461A1 (en) | Antitussive/expectorant compositions | |
CA1117528A (fr) | Phosphate de glaucine | |
JPS62142175A (ja) | (―)エブルナメニン―14―(15h)―オン樹脂酸塩およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |